Trial of Ovarian Vein and Pelvic Vein Embolization in Women With Chronic Pelvic Pain and Pelvic Varices

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorWeill Medical College of Cornell University

About this trial

The purpose of this study is to see if a randomized controlled trial of ovarian vein and pelvic vein embolization versus venography alone could determine outcomes for women with chronic pelvic pain and pelvic varicose veins.

The data gathered will assist in addressing changes in quality of life in patients who have ovarian/pelvic vein embolization versus no embolization.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Pain exacerbated by walking, standing or lifting

Symptoms are at least partially alleviated by lying down

Prolonged post-coital ache

Absence of non-venous origin CPP as determined by Gynecology examination

Disqualifiers

Female <18 years of age

Pregnancy (positive pregnancy test)

Female subject who plans to become pregnant during study period

Female subject who is actively breastfeeding

Trial design

Design model

Parallel

Treatments tested in this trial

  • Transcatheter Venography

    Diagnostic test

    Venographic assessment of ovarian veins and internal iliac veins

  • Bilateral ovarian vein embolization

    Procedure/Surgery

    Intervention will include sclerosis of pelvic varices and coil embolization of the bilateral ovarian veins.

Treatment groups

40 Participants
are divided into 2 treatment groups
Group A: Transcatheter VenographySham comparator 1 intervention
Group B: Bilateral Ovarian Vein EmbolizationExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

Change in Visual Analog Scale (VAS) for pelvic pain

The VAS pain score is a standard scale from 0 to 10, defining 0 as ''no pain'' and 10 ''worst pain possible.''

Time frame
Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up

Secondary outcomes

1

Change in Patient-Reported Outcomes Measurement Information System (PROMIS) 3A Pain Intensity Scale

The Patient-Reported Outcomes Measurement Information System (PROMIS) 3A Pain Intensity Scale assess how much a person hurts. The scale ranges from 1-5, defining 1 as ''no pain'' and 5 ''very severe pain.''

Time frame
Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up
2

Change in Patient-Reported Outcomes Measurement Information System (PROMIS) 10 Pain Intensity Scale

The Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health measures assess an individual's physical, mental, and social health. The scale scores from from 5 to 1 with 5 = "Excellent" and 1= "Poor ".

Time frame
Weekly for 4 weeks prior to Day 1 and at 30, 90 and 180 day follow up
3

Change in Patient Global Impression of Change (PGIC)

The self-report measure Patient Global Impression of Change (PGIC) reflects a patient's belief about the efficacy of treatment. PGIC is a 7 point scale with 1= "Very Much Improved" and 7= "Very Much Worse".

Time frame
30, 90 and 180 day follow up
4

Change in EuroQol five-dimension (EQ-5D) scale

The EuroQol five-dimension (EQ-5D) is a concise, generic measure of self-reported health at each visit. Patients will tick the one box that best describes their health on that day. This scale will measure with one question for each of the five dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.The scale is numbered from 0 to 100. =100 means the best health the patient can imagine and 0 means the worst health the patient can imagine,.

Time frame
Weekly for 4 weeks prior to Day 1. Then at 30, 90 and 180 day follow up

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Weill Medical College of Cornell University

Lead sponsor

Society of Interventional Radiology Foundation

Collaborator

VIVA Physicians

Collaborator

Penumbra Inc.

Collaborator